Development and validation of a repharsed phase- HPLC method for simultaneous determination of rosiglitazone and glimepiride in combined dosage forms and human plasma

Table 4 Validation data for the HPLC analysis of ROS and GLM in spiked human plasma.

Parameters		Concentration added (μg/mL)		Concentration found (μg/mL)		% Found
		ROS	GLM	ROS	GLM	ROS	GLM
Intra-day precision		0.5	0.5	0.4794	0.5033	95.88	100.66
		0.75	0.75	0.7282	0.7157	97.09	95.43
		1.0	1.0	1.0013	0.9821	100.13	98.21
	( $\bar{x}$ )					97.70	98.10
	± S.D.					2.19	2.62
	%RSD					2.24	2.67
	%Error					1.29	1.54
Inter-day precision	1^st day	0.5	0.5	0.4769	0.459	95.38	91.80
	2^nd day	0.75	0.75	0.7457	0.719	99.43	95.87
	3^rd day	1.0	1.0	0.9677	0.939	96.77	93.90
	( $\bar{x}$ )					97.19	93.86
	± S.D.					2.05	2.04
	%RSD					2.11	2.04
	%Error					1.22	1.18

ISSN: 2661-801X